UNSPSC 51112608: Cyclophosphamide anhydrous

This classification denotes a nitrogen mustard compound and immunosuppressant with the molecular formula C7H15Cl2N2O2P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6UXW23996M, chemically known as 2h-1,3,2-oxazaphosphorin-2-amine, n,n-bis(2-chloroethyl)tetrahydro-, 2-oxide, but more generally known as cyclophosphamide anhydrous, which bears US NIH Compound Identifier 2907.

European Medicines Agency schedules cyclophosphamide anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06859MIG. Most nations, for tariff purposes, schedule cyclophosphamide anhydrous under HS 29349990. Cyclophosphamide anhydrous bears US NLM identifiers UMLS ID C1880207 and NCI Concept Code C61694. SMILES: C1CNP(=O)(OC1)N(CCCL)CCCL.

UNSPSC 51112608 Cyclophosphamide anhydrous is a Commodity code representing a specific chemotherapy agent that state and local health agencies procure for their pharmacy benefit and treatment programs. The recent procurement activity under this code shows state health authorities exploring direct-to-manufacturer supply channels for pharmaceutical products, moving beyond traditional intermediaries such as pharmacy benefit managers and group purchasing organizations to negotiate pricing and manage inventory more efficiently. The Texas Health and Human Services Commission issued a Request for Information in April 2026 to solicit vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, indicating that state Medicaid and employee health plans are actively evaluating alternative acquisition models for controlled pharmaceuticals and specialty drugs.

The geographic activity supporting this code centers on Texas, where the HHS Commission's RFI sought vendor experience with direct contracting for self-insured employers and government health plans. The April 2026 RFI represents preliminary market research rather than a formal competitive solicitation, designed to inform the state's future procurement strategy before issuing a formal RFP with binding financial and temporal parameters. Vendors responding to this exploratory phase provided information about their capacity to enter direct contracts outside existing PBM and GPO arrangements, implement value-based pricing models without rebates, and fulfill product volume requirements through dedicated pharmacy partners. No award value, set-asides, or formal evaluation criteria were specified in this information-gathering stage; the state indicated it would use vendor input to develop detailed procurement specifications and implementation timelines for subsequent formal solicitations.